Immunotherapy plus chemotherapy for childhood nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares adding the immunotherapy drug toripalimab to standard chemotherapy (GP) versus chemotherapy alone for children and teens with advanced nasopharyngeal cancer. It aims to see if the combination helps reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 6 and 18 years old
- Newly diagnosed nasopharyngeal cancer (type II or III) that has not spread
- Overall good health (able to do normal activities)
- Adequate blood counts and liver/kidney function
- No prior cancer treatment, and no other active cancer in the past 5 years
- Not pregnant or breastfeeding, and willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.